The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLCHIRSCH, Fred R.Oncogene (Basingstoke). 2009, Vol 28, issn 0950-9232, 47 p., SUP1Serial Issue

Individualized therapy in non-small-cell lung cancer: future versus current clinical practicePEREZ-SOLER, R.Oncogene (Basingstoke). 2009, Vol 28, issn 0950-9232, S38-S45, SUP1Article

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsGAZDAR, A. F.Oncogene (Basingstoke). 2009, Vol 28, issn 0950-9232, S24-S31, SUP1Article

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needsBURRIS, H. A.Oncogene (Basingstoke). 2009, Vol 28, issn 0950-9232, S4-S13, SUP1Article

Companion Diagnostics: Has Their Time Come and Gone?HIRSCH, Fred R; BUNN, Paul A; HERBST, Roy S et al.Clinical cancer research (Print). 2014, Vol 20, Num 17, pp 4422-4424, issn 1078-0432, 3 p.Article

Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?BUNN, Paul A; HIRSCH, Fred R; AISNER, Dara L et al.Clinical cancer research (Print). 2014, Vol 20, Num 7, pp 1727-1729, issn 1078-0432, 3 p.Article

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitorsJOHN, T; LIU, G; TSAO, M.-S et al.Oncogene (Basingstoke). 2009, Vol 28, issn 0950-9232, S14-S23, SUP1Article

Chemoprevention of lung cancer: current status and future prospectsVAN ZANDWIJK, Nico; HIRSCH, Fred R.Lung cancer. 2003, Vol 42, pp S71-S79, issn 0169-5002, SUP1Conference Paper

Expression of target molecules in lung cancer: Challenge for a new treatment paradigmHIRSCH, Fred R; FRANKLIN, Wilbur A; BUNN, Paul A et al.Seminars in oncology. 2002, Vol 29, Num 3, pp 2-8, issn 0093-7754, SUP9Article

Early detection of lung cancer : Clinical perspectives of recent advances in biology and radiologyHIRSCH, Fred R; FRANKLIN, Wilbur A; GAZDAR, Adi F et al.Clinical cancer research. 2001, Vol 7, Num 1, pp 5-22, issn 1078-0432Article

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancerHIRSCH, F. R; VARELLA-GARCIA, M; CAPPUZZO, F et al.Oncogene (Basingstoke). 2009, Vol 28, issn 0950-9232, S32-S37, SUP1Article

KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer : Practical Application of Patient SelectionJIMENO, Antonio; MESSERSMITH, Wells A; HIRSCH, Fred R et al.Journal of clinical oncology. 2009, Vol 27, Num 7, pp 1130-1136, issn 0732-183X, 7 p.Article

Advances in the biology of lung cancer chemopreventionHIRSCH, Fred R; LIPPMAN, Scott M.Journal of clinical oncology. 2005, Vol 23, Num 14, pp 3186-3197, issn 0732-183X, 12 p.Article

Lung cancer screening by spiral CT. What is the optimal target population for screening trials?VAN KLAVEREN, Rob J; DE KONING, Harry J; MULSHINE, James et al.Lung cancer. 2002, Vol 38, Num 3, pp 243-252, issn 0169-5002, 10 p.Article

Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in DenmarkSKULADOTTIR, Halla; HIRSCH, Fred R; HANSEN, Heine H et al.Lung cancer. 2002, Vol 37, Num 2, pp 127-135, issn 0169-5002Article

The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosisBREMNES, Roy M; VEVE, Robert; HIRSCH, Fred R et al.Lung cancer. 2002, Vol 36, Num 2, pp 115-124, issn 0169-5002, 10 p.Article

Targeted molecular mechanisms of epoetin alfaLANGER, Corey J; HIRSCH, Fred R; CORTES-FUNES, Hernan et al.Lung cancer. 2003, Vol 41, pp S133-S145, issn 0169-5002, SUP1Conference Paper

Lung cancer chemoprevention: moving from concept to a realityMULSHINE, James L; HIRSCH, Fred R.Lung cancer. 2003, Vol 41, pp S163-S174, issn 0169-5002, SUP1Conference Paper

Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819REDMAN, Mary W; CROWLEY, John J; HERBST, Roy S et al.Clinical cancer research (Print). 2012, Vol 18, Num 15, pp 4004-4012, issn 1078-0432, 9 p.Article

Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung CancerGLUBB, Dylan M; CERRI, Elisa; LINGEN, Mark W et al.Clinical cancer research (Print). 2011, Vol 17, Num 16, pp 5257-5267, issn 1078-0432, 11 p.Article

Genetic Abnormalities of the EGFR Pathway in African American Patients With Non-Small-Cell Lung CancerLEIDNER, Rom S; PINGFU FU; HIRSCH, Fred R et al.Journal of clinical oncology. 2009, Vol 27, Num 33, pp 5620-5626, issn 0732-183X, 7 p.Article

Sputum Cytologic Atypia Predicts Incident Lung Cancer : Defining Latency and Histologic SpecificityBYERS, Tim; WOLF, Holly J; MILLER, York E et al.Cancer epidemiology, biomarkers & prevention. 2008, Vol 17, Num 1, pp 158-162, issn 1055-9965, 5 p.Article

Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapyBUNN, Paul A; DZIADZIUSZKO, Rafal; VARELLA-GARCIA, Marileila et al.Clinical cancer research. 2006, Vol 12, Num 12, pp 3652-3656, issn 1078-0432, 5 p.Article

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levelsHELFRICH, Barbara A; RABEN, David; HIRSCH, Fred R et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 7117-7125, issn 1078-0432, 9 p.Article

High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypiaKENNEDY, Timothy C; FRANKLIN, Wilbur A; BYERS, Tim et al.Lung cancer. 2005, Vol 49, Num 2, pp 187-191, issn 0169-5002, 5 p.Article